^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mesmulogene ancovacivec (TG4010)

    i
    Other names: MVATG9931, TG4010, MVA- MUC1-IL2, VV-MUC-1-IL2, modified vaccinia ankara encoding human MUC-1 antigen and interleukin-2 suspension
    Associations

    News

    Trials
    Company:
    Transgene
    Drug class:
    Immunostimulant, IL-2 stimulant, MUC1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    Advances in Non-Small Cell Lung Cancer Cellular Immunotherapy: A Progress in Dendritic Cell, T-Cell, and NK Cell Vaccines. (PubMed, Cells)
    T-cell vaccines, designed to activate cytotoxic CD8+ T-cell responses, have been tested across multiple platforms, including peptide-based (MAGE-A3), viral vector (TG4010/MUC1), and mRNA (CV9201/92) formulations. Recent advances include cytokine-enhanced, memory-like NK cells to overcome immunosuppression and "off-the-shelf" products for broader clinical use. Together, these cellular immunotherapies represent a versatile and evolving frontier in NSCLC treatment, with ongoing research optimizing combinations, delivery platforms, and patient selection to maximize therapeutic benefit.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • MUC1 (Mucin 1)
    |
    mesmulogene ancovacivec (TG4010)
    almost4years
    A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=44, Completed, Transgene | Active, not recruiting --> Completed | Trial completion date: Nov 2020 --> Feb 2021
    Clinical • Trial completion • Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • mesmulogene ancovacivec (TG4010)
    4years
    TG4010 and Nivolumab in Patients With Lung Cancer (clinicaltrials.gov)
    P2, N=13, Completed, Karen Kelly | Active, not recruiting --> Completed | N=33 --> 13 | Trial completion date: Aug 2021 --> Feb 2021
    Clinical • Trial completion • Enrollment change • Trial completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK mutation
    |
    Opdivo (nivolumab) • mesmulogene ancovacivec (TG4010)
    5years
    TG4010 and Nivolumab in Patients With Lung Cancer (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, Karen Kelly | Trial completion date: Oct 2020 --> Aug 2021 | Trial primary completion date: Jun 2020 --> Feb 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK mutation
    |
    Opdivo (nivolumab) • mesmulogene ancovacivec (TG4010)
    almost6years
    TG4010 and Nivolumab in Patients With Lung Cancer (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, Karen Kelly | Trial primary completion date: Dec 2019 --> Jun 2020
    Clinical • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK mutation
    |
    Opdivo (nivolumab) • mesmulogene ancovacivec (TG4010)